Circulating DPP4 measurement may represent a novel cost-effective strategy for NAFLD/NASH risk stratification and a potential tool for monitoring disease’s progression in established NAFLD. Here, DPP4 is linked to metabolic dysfunction-associated steatotic liver disease.